Archives

March 5, 2026

USITC Will Investigate State Support and Pricing Practices by Chinese Biotechnology Firms

The U.S. International Trade Commission (USITC) announced on February 26, 2026, that it is undertaking a factfinding investigation to examine Chinese state support and pricing practices in the biotechnology sector and assess how these practices may be affecting the market share and competitiveness of the U.S. industry. USITC states that it is instituting this investigation, “Impact on U.S. Industry of China’s State Support and Pricing Practices in the Biotechnology Sector” (Inv. No....
March 4, 2026

Senate Bill Would Establish Federal Biotechnology Security Framework

On January 29, 2026, Senator Tom Cotton (R-AR) introduced the Biosecurity Modernization and Innovation Act of 2026 (S. 3741) to establish a federal biosecurity framework. According to Cotton’s February 4, 2026, press release, the bill “will require gene synthesis providers screen their orders and customers for bad actors or dangerous pathogens, and will ensure that the U.S. government adopts a flexible and agile approach to biosecurity that will ensure American leadership in biosecurity.”...
February 5, 2026

NSCEB Fact Sheet Offers Biotechnology Solutions for Critical Minerals

On February 4, 2026, the National Security Commission on Emerging Biotechnology (NSCEB) announced the release of a fact sheet on biotechnology solutions for critical minerals. NSCEB notes that the United States is overly reliant on China for critical minerals. According to NSCEB, biotechnology “creates new paths to reduce our reliance on China by unlocking new sources of critical minerals right here in the United States.” NSCEB states that the recently-announced Project Vault and other...
February 4, 2026

OECD Paper Compares Regulatory Environments for Biotechnology and Biosolutions between the EU and United States

The Organisation for Economic Co-operation and Development (OECD) posted a working paper on January 30, 2026, entitled A comparison of the innovation and regulatory environments for biotechnology and biosolutions across the European Union and the United States. According to the authors, the working paper “strengthens the evidence base for biotechnology policymaking by examining two critical dimensions: innovation-enabling conditions and regulatory practices.” Focusing on the European Union...
January 29, 2026

NSCEB Paper Outlines Policy Options to Modernize Oversight of Biotechnology Products

The National Security Commission on Emerging Biotechnology (NSCEB) has published a January 2026 discussion paper entitled “Creating Clear Regulatory Pathways for Biotechnology.” According to the paper, biotechnology regulations in the United States are complex, resulting in a slow process, while regulations in China and other countries allow developers to move ahead more quickly. The paper notes that the regulatory system in the United States is “built on laws that predate biotechnology,...
January 6, 2026

2026 Forecast for U.S. Federal and International Chemical Regulatory Policy

Download a PDF of the Forecast 2026. Bergeson & Campbell, P.C. (B&C®), its global consulting affiliate The Acta Group (Acta®), and consortia management affiliate B&C® Consortia Management, L.L.C. (BCCM) are pleased to share with you our Forecast 2026. Our distinguished global team of chemical experts worked hard to summarize our collective best guess on what to expect in the New Year regarding global industrial, agricultural, and biocidal chemical regulatory and policy...
December 18, 2025

EC Releases Proposed Biotech Act

On December 15, 2025, the European Commission (EC) announced a legislative package that includes a proposal for a regulation to establish measures to strengthen the European Union’s (EU) biotechnology and biomanufacturing sectors (Biotech Act). The questions and answers (Q&A) on the Biotech Act note that the proposal is focused on health biotech, “although it also includes provisions on food and feed.” According to the Q&A, the Biotech Act would amend specific parts of EU health...
December 3, 2025

OECD Policy Brief Explores Biotechnology Investment and Regulatory Policy Landscapes in the EU and United States

On November 23, 2025, the Organisation for Economic Co-operation and Development (OECD) published a policy brief entitled “Boosting biotechnology innovation through agile regulation and finance instruments.” The policy brief explores the investment and regulatory policy landscapes in the European Union (EU) and the United States, “highlighting shared challenges and lessons that can help accelerate sustainable innovation and strengthen participation in the global bioeconomy.” The policy...
May 21, 2025

Congress and the Feds — the Impact of Nonperformance

Ponder the following existential question: Who does their job less effectively? Members of Congress, or employees of federal agencies? Let’s examine the U.S. Environmental Protection Agency (EPA) employees versus those responsible for legislating environmental laws. Congress has not been able to reauthorize environmental statutes for years, with some (most) needing significant attention. EPA relies on 1990 Clean Air Act amendments to sort out air pollution issues and address climate change...
March 20, 2025

President Trump Revokes 2022 EO on Advancing Biotechnology and Biomanufacturing

On March 14, 2025, President Trump signed Executive Order (EO) 14236, rescinding 19 executive actions, including former President Biden’s September 2022 EO 14081, “Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy.” 90 Fed. Reg. 13037. According to the White House’s March 14, 2025, fact sheet, EO 14081 “funneled Federal resources into radical biotech and biomanufacturing initiatives under the guise of environmental...